plumss personal page - To The Moon

plumss

No personal profile

6Follow

0Followers

0Topic

0Badge

2022-02-03

[Surprised] [Surprised] [Surprised]

2 Stocks to Grab Now That the S&P 500 Is In Correction Territory

2022-02-01

[Smile]

Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?

2022-02-10

wow!

Sorry, the original content has been removed

2022-02-05

wow

US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs

2022-02-11

[Great] [Great]

2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4106449593726790","uuid":"4106449593726790","gmtCreate":1643625723216,"gmtModify":1643625723216,"name":"plumss","pinyin":"plumss","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9092839984,"gmtCreate":1644577481256,"gmtModify":1676533942929,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4106449593726790","authorIdStr":"4106449593726790"},"themes":[],"htmlText":"[Great]&nbsp;[Great]&nbsp;","listText":"[Great]&nbsp;[Great]&nbsp;","text":"[Great] [Great]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092839984","repostId":"2210159258","repostType":2,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4512":"苹果概念","BK4566":"资本集团","MMM":"3M","BK4532":"文艺复兴科技持仓","BK4206":"工业集团企业"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096410047,"gmtCreate":1644448879346,"gmtModify":1676533926592,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4106449593726790","authorIdStr":"4106449593726790"},"themes":[],"htmlText":"wow!","listText":"wow!","text":"wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096410047","repostId":"1131170123","repostType":4,"repost":{"id":"1131170123","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1644445838,"share":"https://ttm.financial/m/news/1131170123?lang=&edition=fundamental","pubTime":"2022-02-10 06:30","market":"us","language":"en","title":"Disney Beats Earnings Expectations, Disney+ Subscriptions near 130 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1131170123","media":"Tiger Newspress","summary":"Disney reported earnings for its fiscal first quarter Wednesday that beat analyst estimates on earni","content":"<html><head></head><body><p>Disney reported earnings for its fiscal first quarter Wednesday that beat analyst estimates on earnings per share and revenue.Disney reported better-than-expected subscription numbers for its Disney+ streaming service in the recently completed quarter, reversing a slowdown in sign-ups.</p><p>The stock popped more than 8% in extended trading on the news.</p><p><img src=\"https://static.tigerbbs.com/63f290acc869deea5df361f74a1fc754\" tg-width=\"841\" tg-height=\"619\" width=\"100%\" height=\"auto\"/></p><p>Here are the results.</p><ul><li><b>Earnings per share:</b>$1.06 adj. vs 63 cents expected, according to a Refinitiv survey of analysts</li><li><b>Revenue:</b>$21.82 billion vs $20.91 billion expected, according to Refinitiv</li><li><b>Disney+ total subscriptions:</b>129.8 million vs 125.75 million expected, according to StreetAccount</li></ul><p>Disney Chief Executive Bob Chapek reaffirmed the Disney+ subscriber target of 230 million to 260 million by 2024. The company added 11.8 million Disney+ subscribers in the first quarter.</p><p>And the company forecast stronger subscriber growth in the second half of its year than in the first half.</p><p>U.S. parks and resorts delivered revenue above pre-pandemic levels, but Disney expects international parks to be impacted by COVID for weeks to come.</p><p>The company&#39;s overall revenue rose 34% to $21.82 billion in the quarter ended Jan. 1, topping analysts&#39; estimate of $20.91 billion, according to Refinitiv data.</p><p>Disney+, the company&#39;s two-year-old streaming service kept the business afloat when the pandemic disrupted its legacy theme parks, resorts and cruise operations.</p><p>Now, the relaxing of government restrictions and pent-up demand has led to strong attendance at domestic theme parks as Omicron fears have receded.</p><p>Excluding items, Disney earned $1.06 per share, blowing past Wall Street&#39;s estimate of 63 cents.</p><p>“This marks the final year of the Walt Disney Company’s first century, and performance like this coupled with our unmatched collection of assets and platforms, creative capabilities, and unique place in the culture give me great confidence we will continue to define entertainment for the next 100 years,” said Chapek.</p><p>Revenue in the parks, experiences and products segment more than doubled to $7.23 billion in the first quarter.</p><p>Meanwhile, operating income in the segment stood at $2.45 billion, versus an operating loss of $119 million a year ago.</p><p>Disney+ subscribers stood at 129.8 million at the end of the first quarter, compared with Factset estimates of 129.2 million.</p><p>Investors are watching the streaming service’s growth trajectory as it relates to its ability to reach fiscal 2024 guidance.</p><p>Disney has poured billions into creating new programming to grab a share of the online video market dominated by Netflix Inc , staking its future on a direct-to-consumer strategy.</p><p>Its much anticipated &#34;Obi-Wan Kenobi&#34; series will launch on Disney+ on May 25, Chapek said.</p><p>During the first quarter, Disney+ released the first episode of “The Book of Boba Fett,” about the Star Wars bounty hunter; “The Beatles: Get Back” documentary series from filmmaker Peter Jackson, and “Hawkeye,” about the Marvel superhero.</p><p>Disney announced in November that it would offer a bundle of its three streaming services, Disney+, Hulu and ESPN+, for $13.99 per month.</p><p>In January, Netflix forecast weak first-quarter subscriber growth, which sent shares down nearly 20% and erased most of its remaining pandemic-fueled gains from 2020.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney Beats Earnings Expectations, Disney+ Subscriptions near 130 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney Beats Earnings Expectations, Disney+ Subscriptions near 130 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-10 06:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Disney reported earnings for its fiscal first quarter Wednesday that beat analyst estimates on earnings per share and revenue.Disney reported better-than-expected subscription numbers for its Disney+ streaming service in the recently completed quarter, reversing a slowdown in sign-ups.</p><p>The stock popped more than 8% in extended trading on the news.</p><p><img src=\"https://static.tigerbbs.com/63f290acc869deea5df361f74a1fc754\" tg-width=\"841\" tg-height=\"619\" width=\"100%\" height=\"auto\"/></p><p>Here are the results.</p><ul><li><b>Earnings per share:</b>$1.06 adj. vs 63 cents expected, according to a Refinitiv survey of analysts</li><li><b>Revenue:</b>$21.82 billion vs $20.91 billion expected, according to Refinitiv</li><li><b>Disney+ total subscriptions:</b>129.8 million vs 125.75 million expected, according to StreetAccount</li></ul><p>Disney Chief Executive Bob Chapek reaffirmed the Disney+ subscriber target of 230 million to 260 million by 2024. The company added 11.8 million Disney+ subscribers in the first quarter.</p><p>And the company forecast stronger subscriber growth in the second half of its year than in the first half.</p><p>U.S. parks and resorts delivered revenue above pre-pandemic levels, but Disney expects international parks to be impacted by COVID for weeks to come.</p><p>The company&#39;s overall revenue rose 34% to $21.82 billion in the quarter ended Jan. 1, topping analysts&#39; estimate of $20.91 billion, according to Refinitiv data.</p><p>Disney+, the company&#39;s two-year-old streaming service kept the business afloat when the pandemic disrupted its legacy theme parks, resorts and cruise operations.</p><p>Now, the relaxing of government restrictions and pent-up demand has led to strong attendance at domestic theme parks as Omicron fears have receded.</p><p>Excluding items, Disney earned $1.06 per share, blowing past Wall Street&#39;s estimate of 63 cents.</p><p>“This marks the final year of the Walt Disney Company’s first century, and performance like this coupled with our unmatched collection of assets and platforms, creative capabilities, and unique place in the culture give me great confidence we will continue to define entertainment for the next 100 years,” said Chapek.</p><p>Revenue in the parks, experiences and products segment more than doubled to $7.23 billion in the first quarter.</p><p>Meanwhile, operating income in the segment stood at $2.45 billion, versus an operating loss of $119 million a year ago.</p><p>Disney+ subscribers stood at 129.8 million at the end of the first quarter, compared with Factset estimates of 129.2 million.</p><p>Investors are watching the streaming service’s growth trajectory as it relates to its ability to reach fiscal 2024 guidance.</p><p>Disney has poured billions into creating new programming to grab a share of the online video market dominated by Netflix Inc , staking its future on a direct-to-consumer strategy.</p><p>Its much anticipated &#34;Obi-Wan Kenobi&#34; series will launch on Disney+ on May 25, Chapek said.</p><p>During the first quarter, Disney+ released the first episode of “The Book of Boba Fett,” about the Star Wars bounty hunter; “The Beatles: Get Back” documentary series from filmmaker Peter Jackson, and “Hawkeye,” about the Marvel superhero.</p><p>Disney announced in November that it would offer a bundle of its three streaming services, Disney+, Hulu and ESPN+, for $13.99 per month.</p><p>In January, Netflix forecast weak first-quarter subscriber growth, which sent shares down nearly 20% and erased most of its remaining pandemic-fueled gains from 2020.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131170123","content_text":"Disney reported earnings for its fiscal first quarter Wednesday that beat analyst estimates on earnings per share and revenue.Disney reported better-than-expected subscription numbers for its Disney+ streaming service in the recently completed quarter, reversing a slowdown in sign-ups.The stock popped more than 8% in extended trading on the news.Here are the results.Earnings per share:$1.06 adj. vs 63 cents expected, according to a Refinitiv survey of analystsRevenue:$21.82 billion vs $20.91 billion expected, according to RefinitivDisney+ total subscriptions:129.8 million vs 125.75 million expected, according to StreetAccountDisney Chief Executive Bob Chapek reaffirmed the Disney+ subscriber target of 230 million to 260 million by 2024. The company added 11.8 million Disney+ subscribers in the first quarter.And the company forecast stronger subscriber growth in the second half of its year than in the first half.U.S. parks and resorts delivered revenue above pre-pandemic levels, but Disney expects international parks to be impacted by COVID for weeks to come.The company's overall revenue rose 34% to $21.82 billion in the quarter ended Jan. 1, topping analysts' estimate of $20.91 billion, according to Refinitiv data.Disney+, the company's two-year-old streaming service kept the business afloat when the pandemic disrupted its legacy theme parks, resorts and cruise operations.Now, the relaxing of government restrictions and pent-up demand has led to strong attendance at domestic theme parks as Omicron fears have receded.Excluding items, Disney earned $1.06 per share, blowing past Wall Street's estimate of 63 cents.“This marks the final year of the Walt Disney Company’s first century, and performance like this coupled with our unmatched collection of assets and platforms, creative capabilities, and unique place in the culture give me great confidence we will continue to define entertainment for the next 100 years,” said Chapek.Revenue in the parks, experiences and products segment more than doubled to $7.23 billion in the first quarter.Meanwhile, operating income in the segment stood at $2.45 billion, versus an operating loss of $119 million a year ago.Disney+ subscribers stood at 129.8 million at the end of the first quarter, compared with Factset estimates of 129.2 million.Investors are watching the streaming service’s growth trajectory as it relates to its ability to reach fiscal 2024 guidance.Disney has poured billions into creating new programming to grab a share of the online video market dominated by Netflix Inc , staking its future on a direct-to-consumer strategy.Its much anticipated \"Obi-Wan Kenobi\" series will launch on Disney+ on May 25, Chapek said.During the first quarter, Disney+ released the first episode of “The Book of Boba Fett,” about the Star Wars bounty hunter; “The Beatles: Get Back” documentary series from filmmaker Peter Jackson, and “Hawkeye,” about the Marvel superhero.Disney announced in November that it would offer a bundle of its three streaming services, Disney+, Hulu and ESPN+, for $13.99 per month.In January, Netflix forecast weak first-quarter subscriber growth, which sent shares down nearly 20% and erased most of its remaining pandemic-fueled gains from 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098330408,"gmtCreate":1644022842365,"gmtModify":1676533882359,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4106449593726790","authorIdStr":"4106449593726790"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098330408","repostId":"1197042929","repostType":2,"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091536030,"gmtCreate":1643896954609,"gmtModify":1676533868802,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4106449593726790","authorIdStr":"4106449593726790"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091536030","repostId":"2208395282","repostType":4,"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9093427088,"gmtCreate":1643689978010,"gmtModify":1676533845013,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4106449593726790","authorIdStr":"4106449593726790"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093427088","repostId":"2207226382","repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4555":"新能源车","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","GM":"通用汽车","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4176":"多领域控股","BMY":"施贵宝","BK4099":"汽车制造商","BK4559":"巴菲特持仓","TEVA":"梯瓦制药","BK4557":"大麻股","BRK.A":"伯克希尔","BK4561":"索罗斯持仓","BK4534":"瑞士信贷持仓","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9091536030,"gmtCreate":1643896954609,"gmtModify":1676533868802,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106449593726790","idStr":"4106449593726790"},"themes":[],"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091536030","repostId":"2208395282","repostType":4,"repost":{"id":"2208395282","pubTimestamp":1643889086,"share":"https://ttm.financial/m/news/2208395282?lang=&edition=fundamental","pubTime":"2022-02-03 19:51","market":"us","language":"en","title":"2 Stocks to Grab Now That the S&P 500 Is In Correction Territory","url":"https://stock-news.laohu8.com/highlight/detail?id=2208395282","media":"Motley Fool","summary":"Take advantage of the market's short-term mindset and buy these two long-term winners.","content":"<html><head></head><body><p>When a stock or index falls 10% from its all-time high, it is said to be in correction territory. While this isn&#39;t as scary-sounding as a bear market -- denoted by a 20% fall -- it should give investors pause. Corrections often occur because of an event, and stocks are indiscriminately sold across the board.</p><p>A wide sell-off gives investors opportunities to grab stocks that may be caught up in the frenzy but whose business will be unaffected. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> stocks I believe are great buys are <b>Shopify </b>(NYSE:SHOP) and <b>Alphabet</b> (NASDAQ:GOOG) (NASDAQ:GOOGL). Each has seen its stock price fall recently, but the businesses are still thriving.</p><h2>1. Shopify</h2><p>Starting a business can be difficult; selling the product online can be even more challenging. Shopify simplifies the process by providing website templates, payment processing, and shipping solutions at an affordable $29 per month. As a business grows and can afford to expand its e-commerce tool kit, Shopify has other tiers with upgraded features.</p><p>It&#39;s not just a small business enabler. Many large brands like <b>Kraft Heinz </b>and KKW Beauty -- Kim Kardashian&#39;s cosmetic line -- use its software. Shopify recently announced it was expanding its offerings for larger companies by providing two-day shipping and easy returns. An undertaking like this requires significant investment in warehouse space. Fortunately, Shopify is forward-thinking and already acquired 6 River Systems -- a robotic warehouse company -- to provide top-notch automation within the facilities. Shopify is providing best-in-class e-commerce solutions to businesses of all sizes, and this latest move reinforces that notion.</p><p>The company splits its revenue into two segments, merchant and subscription solutions. Subscription solutions are the base prices customers pay each month to access the tools Shopify offers. Growth in this segment can occur through two main avenues: New customers, or customers upgrading tiers. During the third quarter, Shopify&#39;s subscription solution grew 37% year over year to $336 million, but only made up 30% of revenue.</p><p>The larger segment, merchant solutions, grows as the stores on its platform increase their sales. As Shopify&#39;s customers do better, it does better. With merchant solutions up 51% year over year to $788 million, it&#39;s clear that countless businesses on Shopify are succeeding.</p><p>Shopify isn&#39;t consistently profitable and is best valued by comparing its stock price with its revenue, captured by the price-to-sales (PS) metric.</p><p><img src=\"https://static.tigerbbs.com/78410274e2bde12a83ef6462d23bce93\" tg-width=\"720\" tg-height=\"433\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>SHOP PS Ratio data by YCharts</p><p>After an elevated valuation during most of 2020 and 2021, Shopify&#39;s PS ratio has returned to pre-pandemic levels after the recent sell-off. While investors shouldn&#39;t expect Shopify to return to previous valuation highs, revenue growth going forward should directly correlate with its stock price if current valuation levels are maintained. With revenue growing 46% overall and Shopify expanding with larger businesses, the future is bright for the company&#39;s stock.</p><h2>2. Alphabet</h2><p>Contrasting Shopify&#39;s high growth and unprofitability is Alphabet -- the parent company of Google and YouTube -- which also has high growth but is insanely profitable. With its search engine and video sharing market dominance, Alphabet&#39;s primary offerings are unlikely to be disrupted by competitors.</p><table border=\"1\"><tbody><tr><th>Segment</th><th>Market Share</th></tr><tr><td>Google Search Engine</td><td>86%</td></tr><tr><td>YouTube</td><td>76%</td></tr></tbody></table><p>Data source: Statista and Datanyze.</p><p>Because of each segment&#39;s supremacy, it can offer advertisers a diverse audience, making Alphabet a valuable advertising partner. While advertising spending grew marginally during 2020, 2021 was a different story. Google&#39;s Q3 search ad revenue grew 44% to $37.9 billion -- for context, Shopify&#39;s gross merchandise volume for Q3 was $41.8 billion. Comparing the incredible 44% growth with Q3 2020&#39;s mere 3% showcases how advertising businesses fare during difficult economic times. On the YouTube side, growth was similar at 43%, but revenue was much less than its search engine division at $7.2 billion.</p><p>At its core, Alphabet is an advertising business. Because advertisement spending tends to drop during recessions -- it dropped by 13% across the board during the 2008 recession -- Alphabet will likely receive a lower valuation due to this risk.</p><p><img src=\"https://static.tigerbbs.com/fe1f802170b39b9e567e64d0288e7aad\" tg-width=\"720\" tg-height=\"433\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>GOOG PE Ratio data by YCharts</p><p>Still, a 29 price-to-earnings ratio is dirt cheap for a company growing its earnings at a 71% clip. As long as the economy doesn&#39;t grind to a halt, Alphabet&#39;s advertisement business will continue providing absurd growth numbers.</p><p>One division that isn&#39;t a market leader is Google Cloud. It only has an 8% market share versus <b>Amazon</b> Web Services&#39; 32% and <b>Microsoft </b>Azure&#39;s 21%, according to Statista. With Azure growing 46% during the fourth quarter, investors need to watch Alphabet&#39;s Q4 earnings report to see if Google Cloud is gaining ground or if it is struggling against its bigger competitors. Regardless, if advertisement revenue continues to increase, Alphabet will still report strong earnings.</p><p>With most of the correction concerns circling around interest rate hikes by the Federal Reserve, it hardly affects Shopify&#39;s and Alphabet&#39;s business. Although the stock prices may mean some short-term pain, each business is focused on the long term, just like investors should be. Purchasing both these stocks on sale and holding for three to five years allows investors to reap the benefits of a growing business while riding out any market-induced volatility in the stock prices. Both these stocks are attractively valued, so it could be a great time to take advantage of the market&#39;s short-term thinking to own two long-term winners today.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Stocks to Grab Now That the S&P 500 Is In Correction Territory</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Stocks to Grab Now That the S&P 500 Is In Correction Territory\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 19:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/03/2-stocks-to-grab-now-that-the-sp-500-is-in-correct/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When a stock or index falls 10% from its all-time high, it is said to be in correction territory. While this isn't as scary-sounding as a bear market -- denoted by a 20% fall -- it should give ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/03/2-stocks-to-grab-now-that-the-sp-500-is-in-correct/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings","SPY":"标普500ETF","GOOG":"谷歌","SHOP":"Shopify Inc","GOOGL":"谷歌A"},"source_url":"https://www.fool.com/investing/2022/02/03/2-stocks-to-grab-now-that-the-sp-500-is-in-correct/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208395282","content_text":"When a stock or index falls 10% from its all-time high, it is said to be in correction territory. While this isn't as scary-sounding as a bear market -- denoted by a 20% fall -- it should give investors pause. Corrections often occur because of an event, and stocks are indiscriminately sold across the board.A wide sell-off gives investors opportunities to grab stocks that may be caught up in the frenzy but whose business will be unaffected. Two stocks I believe are great buys are Shopify (NYSE:SHOP) and Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL). Each has seen its stock price fall recently, but the businesses are still thriving.1. ShopifyStarting a business can be difficult; selling the product online can be even more challenging. Shopify simplifies the process by providing website templates, payment processing, and shipping solutions at an affordable $29 per month. As a business grows and can afford to expand its e-commerce tool kit, Shopify has other tiers with upgraded features.It's not just a small business enabler. Many large brands like Kraft Heinz and KKW Beauty -- Kim Kardashian's cosmetic line -- use its software. Shopify recently announced it was expanding its offerings for larger companies by providing two-day shipping and easy returns. An undertaking like this requires significant investment in warehouse space. Fortunately, Shopify is forward-thinking and already acquired 6 River Systems -- a robotic warehouse company -- to provide top-notch automation within the facilities. Shopify is providing best-in-class e-commerce solutions to businesses of all sizes, and this latest move reinforces that notion.The company splits its revenue into two segments, merchant and subscription solutions. Subscription solutions are the base prices customers pay each month to access the tools Shopify offers. Growth in this segment can occur through two main avenues: New customers, or customers upgrading tiers. During the third quarter, Shopify's subscription solution grew 37% year over year to $336 million, but only made up 30% of revenue.The larger segment, merchant solutions, grows as the stores on its platform increase their sales. As Shopify's customers do better, it does better. With merchant solutions up 51% year over year to $788 million, it's clear that countless businesses on Shopify are succeeding.Shopify isn't consistently profitable and is best valued by comparing its stock price with its revenue, captured by the price-to-sales (PS) metric.SHOP PS Ratio data by YChartsAfter an elevated valuation during most of 2020 and 2021, Shopify's PS ratio has returned to pre-pandemic levels after the recent sell-off. While investors shouldn't expect Shopify to return to previous valuation highs, revenue growth going forward should directly correlate with its stock price if current valuation levels are maintained. With revenue growing 46% overall and Shopify expanding with larger businesses, the future is bright for the company's stock.2. AlphabetContrasting Shopify's high growth and unprofitability is Alphabet -- the parent company of Google and YouTube -- which also has high growth but is insanely profitable. With its search engine and video sharing market dominance, Alphabet's primary offerings are unlikely to be disrupted by competitors.SegmentMarket ShareGoogle Search Engine86%YouTube76%Data source: Statista and Datanyze.Because of each segment's supremacy, it can offer advertisers a diverse audience, making Alphabet a valuable advertising partner. While advertising spending grew marginally during 2020, 2021 was a different story. Google's Q3 search ad revenue grew 44% to $37.9 billion -- for context, Shopify's gross merchandise volume for Q3 was $41.8 billion. Comparing the incredible 44% growth with Q3 2020's mere 3% showcases how advertising businesses fare during difficult economic times. On the YouTube side, growth was similar at 43%, but revenue was much less than its search engine division at $7.2 billion.At its core, Alphabet is an advertising business. Because advertisement spending tends to drop during recessions -- it dropped by 13% across the board during the 2008 recession -- Alphabet will likely receive a lower valuation due to this risk.GOOG PE Ratio data by YChartsStill, a 29 price-to-earnings ratio is dirt cheap for a company growing its earnings at a 71% clip. As long as the economy doesn't grind to a halt, Alphabet's advertisement business will continue providing absurd growth numbers.One division that isn't a market leader is Google Cloud. It only has an 8% market share versus Amazon Web Services' 32% and Microsoft Azure's 21%, according to Statista. With Azure growing 46% during the fourth quarter, investors need to watch Alphabet's Q4 earnings report to see if Google Cloud is gaining ground or if it is struggling against its bigger competitors. Regardless, if advertisement revenue continues to increase, Alphabet will still report strong earnings.With most of the correction concerns circling around interest rate hikes by the Federal Reserve, it hardly affects Shopify's and Alphabet's business. Although the stock prices may mean some short-term pain, each business is focused on the long term, just like investors should be. Purchasing both these stocks on sale and holding for three to five years allows investors to reap the benefits of a growing business while riding out any market-induced volatility in the stock prices. Both these stocks are attractively valued, so it could be a great time to take advantage of the market's short-term thinking to own two long-term winners today.","news_type":1},"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9093427088,"gmtCreate":1643689978010,"gmtModify":1676533845013,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106449593726790","idStr":"4106449593726790"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093427088","repostId":"2207226382","repostType":4,"repost":{"id":"2207226382","pubTimestamp":1643674838,"share":"https://ttm.financial/m/news/2207226382?lang=&edition=fundamental","pubTime":"2022-02-01 08:20","market":"us","language":"en","title":"Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?","url":"https://stock-news.laohu8.com/highlight/detail?id=2207226382","media":"Motley Fool","summary":"Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.","content":"<html><head></head><body><p><b>Berkshire Hathaway</b> CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett&#39;s core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.</p><p>And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire&#39;s stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.</p><p><img src=\"https://static.tigerbbs.com/6d9a90b9030efaa614666da83153f552\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Image source: Getty Images.</p><p>Berkshire&#39;s various holdings aren&#39;t all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.</p><p>As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the <a href=\"https://laohu8.com/S/AONE.U\">one</a> available to ordinary retail investors via a company&#39;s common stock. Retail investors, in turn, shouldn&#39;t necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.</p><p>Armed with this insight, let&#39;s break down whether Berkshire&#39;s three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.</p><h2>A top big pharma stock</h2><p>At a hair under eight times forward earnings, the pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY) is Berkshire&#39;s third-cheapest stock holding at the moment. Bristol&#39;s shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.</p><p>While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.</p><p>The long and short of it is that this isn&#39;t Bristol&#39;s first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn&#39;t hesitate to capitalize on the market&#39;s overreaction to the pharma titan&#39;s ongoing portfolio churn.</p><h2>A potential sleeping giant</h2><p>Shares of the large-cap automaker <b>General Motors</b> (NYSE:GM) are currently trading at 7.43 times forward earnings. That&#39;s good for second place on Berkshire&#39;s list of cheapest stock holdings. The auto giant&#39;s stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.</p><p>General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.</p><p>That said, General Motors&#39; latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.</p><h2>Buffett&#39;s cheapest stock holding</h2><p>With its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is Berkshire&#39;s cheapest stock holding by a wide margin.</p><p>The drugmaker&#39;s shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis&#39; generic drug portfolio back in 2016, it didn&#39;t have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.</p><p>Teva&#39;s long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva&#39;s ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva&#39;s stock thus appears poised for a major rebound, perhaps as soon as this year.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAre Warren Buffett's 3 Cheapest Stocks Screaming Buys?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-01 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4555":"新能源车","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","GM":"通用汽车","BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4176":"多领域控股","BMY":"施贵宝","BK4099":"汽车制造商","BK4559":"巴菲特持仓","TEVA":"梯瓦制药","BK4557":"大麻股","BRK.A":"伯克希尔","BK4561":"索罗斯持仓","BK4534":"瑞士信贷持仓","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2022/01/31/are-warren-buffetts-3-cheapest-stocks-screaming-bu/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2207226382","content_text":"Berkshire Hathaway CEO and world-renowned superinvestor Warren Buffett is a dyed-in-the-wool value investor. Buffett's core strategy centers around buying shares of companies with remarkably strong underlying businesses (deep competitive moats, global brand recognition, reliable and growing free cash flows, etc.), yet whose shares trade at a discount relative to their intrinsic value.And this value-oriented approach has certainly served Buffett well during his tenure as Berkshire CEO. Since taking the reins of the diversified holding company 56-plus years ago, Berkshire's stock has delivered total returns on capital in excess of 6,450%. In fact, $10,000 invested in Berkshire stock at the time Buffett become CEO would be worth approximately $654,890 today.Image source: Getty Images.Berkshire's various holdings aren't all top value stocks, however. The reality of the situation is that Berkshire, along with most other mega-funds, often gets special incentives, such as an elevated dividend yield, to buy shares of a company in bulk.As a result, the value proposition offered to large holding firms like Berkshire is often drastically different than the one available to ordinary retail investors via a company's common stock. Retail investors, in turn, shouldn't necessarily buy shares of a Buffett stock simply because it looks cheap based on a classic valuation metric such as price to earnings, price to book, or price to sales.Armed with this insight, let's break down whether Berkshire's three cheapest holdings, based on their forward-looking price-to-earnings ratios, are bona fide value stocks suitable for retail investors.A top big pharma stockAt a hair under eight times forward earnings, the pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) is Berkshire's third-cheapest stock holding at the moment. Bristol's shares have essentially treaded water over the past year due to its three top-selling medications (Eliquis, Opdivo, and Revlimid) losing market exclusivity this decade.While this wave of patent expirations may be worrisome at first glance, the drugmaker does have a solid plan in place to not only offset these future sales declines, but to keep its top line humming along all the way out to 2030. Namely, Bristol has multiple new drug launches planned over the next few years, several of which are for potential blockbuster medications.The long and short of it is that this isn't Bristol's first bout with the patent cliff. The company has lost market exclusivity for scores of blockbuster medications in the past. Yet it has always managed to hit on new growth products to create enormous value for long-term shareholders. Value-oriented investors, in turn, shouldn't hesitate to capitalize on the market's overreaction to the pharma titan's ongoing portfolio churn.A potential sleeping giantShares of the large-cap automaker General Motors (NYSE:GM) are currently trading at 7.43 times forward earnings. That's good for second place on Berkshire's list of cheapest stock holdings. The auto giant's stock has stagnated over the last year in response to the rise of electric vehicles, the market-wide disinterest in classic value stocks, and the upcoming interest rate hikes by the Federal Reserve that will surely make monthly payments more expensive for most car buyers.General Motors, though, may have some magic in it that the market has yet to fully appreciate. Last summer, the car giant announced an intriguing plan to invest heavily in electric vehicles, autonomous vehicles, and batteries. With a global commercial footprint and rock solid branding power, General Motors could prove to be a formidable competitor in these high-growth segments of the market.That said, General Motors' latent value proposition, albeit massive, may take a few years to win over investors. So, while this auto stock does come across as a compelling buy, this Buffett value stock will likely require a multi-year holding period to realize its full potential.Buffett's cheapest stock holdingWith its shares trading at 3.12 times forward earnings, Israeli generic and branded drug giant Teva Pharmaceutical Industries (NYSE:TEVA) is Berkshire's cheapest stock holding by a wide margin.The drugmaker's shares have lost three-quarters of their value over the last five years due to a series of unfortunate events. Specifically, Teva took on far too much debt to acquire Actavis' generic drug portfolio back in 2016, it didn't have another franchise-level medication waiting in the wings to replace the multiple sclerosis drug Copaxone following its loss of exclusivity, and it has been embroiled in a string of costly lawsuits.Teva's long-awaited turnaround, though, does seem to be coming into focus now, thanks to three key developments. First, the company has slowly built a well-rounded product portfolio that should return it to sustainable levels of growth soon. Second, its various legal problems ought to be resolved in the not-so-distant future. Third, Teva's ongoing deleveraging process has significantly improved the health of its balance sheet over the past few years. Teva's stock thus appears poised for a major rebound, perhaps as soon as this year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":391,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096410047,"gmtCreate":1644448879346,"gmtModify":1676533926592,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106449593726790","idStr":"4106449593726790"},"themes":[],"htmlText":"wow!","listText":"wow!","text":"wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096410047","repostId":"1131170123","repostType":4,"isVote":1,"tweetType":1,"viewCount":491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098330408,"gmtCreate":1644022842365,"gmtModify":1676533882359,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106449593726790","idStr":"4106449593726790"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098330408","repostId":"1197042929","repostType":2,"repost":{"id":"1197042929","pubTimestamp":1644019993,"share":"https://ttm.financial/m/news/1197042929?lang=&edition=fundamental","pubTime":"2022-02-05 08:13","market":"us","language":"en","title":"US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs","url":"https://stock-news.laohu8.com/highlight/detail?id=1197042929","media":"Renaissance Capital","summary":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filer","content":"<html><head></head><body><p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.</p><p>CAR-T biotech <b>Arcellx</b>(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.</p><p>Micro-cap <b>Nuvectis Pharma</b>(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.</p><p>Four SPACs went public this past week led by energy-focused <b>Kimbell Tiger Acquisition</b>(TGR.U), which raised $200 million.</p><p>Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.</p><p><img src=\"https://static.tigerbbs.com/22de4feaa891ad24bf024c86842bc21a\" tg-width=\"1270\" tg-height=\"526\" width=\"100%\" height=\"auto\"/></p><p>One IPO submitted an initial filing: UK-based cannabis firm <b>Akanda</b>(AKAN) filed to raise $20 million.</p><p>Four SPACs submitted initial filings led by <b>Seven Oaks Acquisition II</b>(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.</p><p><img src=\"https://static.tigerbbs.com/9a5668953e00ee47124c91a62d5fab59\" tg-width=\"1271\" tg-height=\"460\" width=\"100%\" height=\"auto\"/></p><p><b>IPO Market Snapshot</b></p><p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&amp;P 500 was down 6.0%. Renaissance Capital&#39;s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.</p></body></html>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Weekly Recap: The February IPO market kicks off with 2 biotechs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Weekly Recap: The February IPO market kicks off with 2 biotechs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 08:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACLX":"ARCELLX, INC.","NVCT":"Nuvectis Pharma, Inc.","TGR.AU":"Tassal Group"},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/90739/US-IPO-Weekly-Recap-The-February-IPO-market-kicks-off-with-2-biotechs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197042929","content_text":"The February IPO market kicked off with two cancer-focused biotechs, joined by four SPACs. New filers trickled into the pipeline with one IPO and four SPACs submitting initial filings.CAR-T biotech Arcellx(ACLX) priced at the low end to raise $124 million at a $583 million market cap. The company’s sole clinical-stage candidate, CART-ddBCMA, reported strong initial Phase 1 data in 19 evaluable relapsed or refractory multiple myeloma patients, delivering a 100% overall response rate. Arcellx currently plans to initiate a Phase 2 trial in late 2022, which it believes will be sufficient to submit a BLA. Arcellx finished up 12%.Micro-cap Nuvectis Pharma(NVCT) priced at the low end of the downwardly revised range to raise $16 million at a $65 million market cap. Nuvectis is currently developing two in-licensed candidates. Its lead candidate began a Phase 1 trial for advanced solid tumors in December 2021, and the other candidate is in preclinical development. Nuvectis finished down 35%.Four SPACs went public this past week led by energy-focused Kimbell Tiger Acquisition(TGR.U), which raised $200 million.Trading in the IPO market continues to be volatile. New issuers delivered mixed performances during January, and the IPO Index capped off a red month with its best day since 2020, though the rise was short-lived.One IPO submitted an initial filing: UK-based cannabis firm Akanda(AKAN) filed to raise $20 million.Four SPACs submitted initial filings led by Seven Oaks Acquisition II(SVOBU), which filed to raise $250 million to target businesses with good ESG practices.IPO Market SnapshotThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 2/3/2022, the Renaissance IPO Index was down 24.6% year-to-date, while the S&P 500 was down 6.0%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Uber Technologies (UBER) and Snowflake (SNOW). The Renaissance International IPO Index was down 11.4% year-to-date, while the ACWX was down 2.5%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Volvo Car Group and Kuaishou.","news_type":1},"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9092839984,"gmtCreate":1644577481256,"gmtModify":1676533942929,"author":{"id":"4106449593726790","authorId":"4106449593726790","name":"plumss","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4106449593726790","idStr":"4106449593726790"},"themes":[],"htmlText":"[Great]&nbsp;[Great]&nbsp;","listText":"[Great]&nbsp;[Great]&nbsp;","text":"[Great] [Great]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092839984","repostId":"2210159258","repostType":2,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4512":"苹果概念","BK4566":"资本集团","MMM":"3M","BK4532":"文艺复兴科技持仓","BK4206":"工业集团企业"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}